Articles producció científicaMedicina i Cirurgia

Secretory Phospholipase A2-IIA and Cardiovascular Disease: A Mendelian Randomization Study.

  • Identification data

    Identifier:  PC:515
    Handle: https://hdl.handle.net/20.500.11797/PC515
    Authors:  Holmes, M.V.; Simon, T.; Exeter, H.J; Folkersen, L.; Asselbergs, F.W.; Guardiola, M.; Cooper, J.A.; Palmen, J.; Hubacek, J.A.; Carruthers, K.F.; Horne, B.D.; Brunisholz, K.D.; Mega, J.L.; Van Iperen, E.P.; Li, M.; Leusink, M.; Trompet, S.; Verschuren, J.J.; Hovingh, G.K.; Dehghan, A.; Nelson, C.P.; Kotti, S.; Danchin, N.; Scholz, M.; Haase, C.L.; Rothenbacher, D.; Swerdlow, D.I.; Kuchenbaecker, K.B.; Staines-Urias, E.; Goel, A.; Van 't Hooft, F.; Gertow, K.; De Faire, U.; Panayiotou, A.G.; Tremoli, E., Baldassarre, D.; Veglia, F.; Holdt, L.M.; Beutner, F.; Gansevoort. R.T.; Navis, G.J.; Mateo, L.I.; Breitling, L.P.; Brenner, H.; Thiery, J.; Dallmeier, D.; Franco-Cereceda, A.; Boer, J.M.; Stephens, J.W.; Hofker, M.H.; Tedgui, A.; Hofman, A.; Uitterlinden, A.G.; Adamkova, V.; Pitha, J.; Onland-Moret, N.C.; Cramer, M.J.; Nathoe, H.M.; Spiering, W.; Klungel, O.H.; Kumari, M.; Whincup, P.H.; Morrow, D.A.; Braund, P.S.; Hall, A.S.; Olsson, A.G.; Doevendans, P.A.; Trip, M.D.; Tobin, M.D.; Hamsten, A.; Watkins, H.; Koenig, W.; Nicolaides, A.N.; Teupser, D.; Day, I.N.; Carlquist, J.F.; Gaunt, T.R.; Ford, I.; Sattar, N.; Tsimikas, S.; Schwartz, G.G.; Lawlor, D.A.; Morris, R.W.; Sandhu, M.S.; Poledne, R.; Maitland-van der Zee, A.H.; Khaw, K.T.; Keating, B.J.; Van der Harst, P.; Price, J.F.; Mehta, S.R.; Yusuf, S.; Witteman, J.C.; Franco, O.H.; Jukema, J.W.; De Knijff, P.; Tybjaerg-Hansen, A.; Rader, D.J.; Farrall, M.; Samani, N.J.; Kivimaki, M.; Fox, K.A.; Humphries, S.E.; Anderson, J.L.; Boekholdt, S.M.; Palmer, T.M.; Eriksson, P.; Paré, G.; Hingorani, A.D.; Sabatine, M.S.; Mallat, Z.; Casas, J.P.; Talmud, P.J.
    Abstract:
    This study sought to investigate the role of secretory phospholipase A2(sPLA2)-IIA in cardiovascular disease. Higher circulating levels of sPLA2-IIA mass or sPLA2enzyme activity have been associated with increased risk ofcardiovascular events. However, it is not clear if this association is causal. A recent phase III clinical trial of an sPLA2inhibitor (varespladib) was stopped prematurely for lack of efficacy

  • Others:

    Link to the original source: https://www.sciencedirect.com/science/article/pii/S0735109713027782?via%3Dihub
    Article's DOI: https://doi.org/10.1016/j.jacc.2013.06.044
    Journal publication year: 2013
    Entity: Universitat Rovira i Virgili.
    Paper version: info:eu-repo/semantics/publishedVersion
    First page: 1966
    URV's Author/s: Guardiola, M., Michael V Holmes, Lasse Folkersen, Tabassome Simon
    Department: Medicina i Cirurgia
    Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
    Last page: 1976
    ISSN: 0735-1097
    Author, as appears in the article.: Holmes, M.V., Simon, T., Exeter, H.J, Folkersen, L., Asselbergs, F.W., Guardiola, M., Cooper, J.A., Palmen, J., Hubacek, J.A., Carruthers, K.F., Horne, B.D., Brunisholz, K.D., Mega, J.L., Van Iperen, E.P., Li, M., Leusink, M., Trompet, S., Verschuren, J.J., Hovingh, G.K., Dehghan, A., Nelson, C.P., Kotti, S., Danchin, N., Scholz, M., Haase, C.L., Rothenbacher, D., Swerdlow, D.I., Kuchenbaecker, K.B., Staines-Urias, E., Goel, A., Van 't Hooft, F., Gertow, K., De Faire, U., Panayiotou, A.G., Tremoli, E., Baldassarre, D., Veglia, F., Holdt, L.M., Beutner, F., Gansevoort. R.T., Navis, G.J., Mateo, L.I., Breitling, L.P., Brenner, H., Thiery, J., Dallmeier, D., Franco-Cereceda, A., Boer, J.M., Stephens, J.W., Hofker, M.H., Tedgui, A., Hofman, A., Uitterlinden, A.G., Adamkova, V., Pitha, J., Onland-Moret, N.C., Cramer, M.J., Nathoe, H.M., Spiering, W., Klungel, O.H., Kumari, M., Whincup, P.H., Morrow, D.A., Braund, P.S., Hall, A.S., Olsson, A.G., Doevendans, P.A., Trip, M.D., Tobin, M.D., Hamsten, A., Watkins, H., Koenig, W., Nicolaides, A.N., Teupser, D., Day, I.N., Carlquist, J.F., Gaunt, T.R., Ford, I., Sattar, N., Tsimikas, S., Schwartz, G.G., Lawlor, D.A., Morris, R.W., Sandhu, M.S., Poledne, R., Maitland-van der Zee, A.H., Khaw, K.T., Keating, B.J., Van der Harst, P., Price, J.F., Mehta, S.R., Yusuf, S., Witteman, J.C., Franco, O.H., Jukema, J.W., De Knijff, P., Tybjaerg-Hansen, A., Rader, D.J., Farrall, M., Samani, N.J., Kivimaki, M., Fox, K.A., Humphries, S.E., Anderson, J.L., Boekholdt, S.M., Palmer, T.M., Eriksson, P., Paré, G., Hingorani, A.D., Sabatine, M.S., Mallat, Z., Casas, J.P., Talmud, P.J.
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    Journal volume: 62
    e-ISSN: 1558-3597

  • Keywords:

    Cardiovascular diseases; Drug development; Epidemiology; Genetics; Mendelian randomization

  • Documents:

    DocumentPrincipal

  • Cerca a google

    Search to google scholar